Unchalee Permsuwan

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Topics

Oral Anticoagulants

Palliative Care

Ejection Fraction

Top Venues

Diabetes therapy : research, treatment and education of diabetes and related disorders

ClinicoEconomics and outcomes research : CEOR

Applied health economics and health policy

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Rungroj Krittayaphong, Unchalee Permsuwan
Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand. Applied health economics and health policy 22 (5) (2024)
Rungroj Krittayaphong, Unchalee Permsuwan
Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand. Applied health economics and health policy (2024)
Rungroj Krittayaphong, Unchalee Permsuwan
Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand. Applied health economics and health policy 22 (5) (2024)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai R Rhee, Unchalee Permsuwan
Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai R Rhee, Unchalee Permsuwan
Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (3) (2023)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai R Rhee, Unchalee Permsuwan
Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (3) (2023)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai A Rhee, Unchalee Permsuwan
Correction to: Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai R Rhee, Unchalee Permsuwan
Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (3) (2023)
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai R Rhee, Unchalee Permsuwan
Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (3) (2023)
Phatcharaphorn Chotnoppharatphatthara, Voratima Yoodee, Suthinee Taesotikul, Jirawit Yadee, Unchalee Permsuwan
Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis. The European journal of health economics : HEPAC : health economics in prevention and care (2022)
Unchalee Permsuwan, Voratima Yoodee, Wacin Buddhari, Nattawut Wongpraparut, Tasalak Thonghong, Sirichai Cheewatanakornkul, Krissada Meemook, Pranya Sakiyalak, Pongsanae Duangpakdee, Jirawit Yadee
Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand. ClinicoEconomics and outcomes research : CEOR 14 (2022)
Rungroj Krittayaphong, Unchalee Permsuwan
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. American journal of cardiovascular drugs : drugs, devices, and other interventions 22 (5) (2022)
Kriengsak Vareesangthip, Chaicharn Deerochanawong, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan
Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Advances in therapy 39 (3) (2022)
Rungroj Krittayaphong, Unchalee Permsuwan
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. Clinical drug investigation 41 (10) (2021)
Chaicharn Deerochanawong, Kriengsak Vareesangthip, Dilok Piyayotai, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan
Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand. Diabetes therapy : research, treatment and education of diabetes and related disorders 12 (7) (2021)
Unchalee Permsuwan, Arintaya Phrommintikul, Voratima Silavanich
Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Suwaporn Songsermlosakul, Unchalee Permsuwan, Wanchana Singhan
Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Rungroj Krittayaphong, Jirawit Yadee, Unchalee Permsuwan
Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction. ClinicoEconomics and outcomes research : CEOR 11 (2019)